{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-011046","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2023-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.029170+00:00","generated_at":"2026-06-14T01:49:57.044885+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Capricor Therapeutics shareholders elect all seven director nominees and approve all proposals at 2023 Annual Meeting","bullets":["Seven director nominees elected: Litvack, Marbán, Musket, Dunbar, Manzo, Collier, Es Sabar (FOR votes 4.9M-5.9M; ~9.4M broker non-votes).","Rose, Snyder & Jacobs LLP ratified as auditor for FY2023: 14.6M FOR, 0.4M AGAINST, 1.3M abstain.","Non-binding advisory vote on named executive officer compensation approved: 4.3M FOR, 2.4M AGAINST, 0.2M abstain.","Amendment to Certificate of Incorporation for officer exculpation approved: 5.0M FOR, 1.8M AGAINST, 0.1M abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-011046","json":"https://secwatch.observer/filing/0001558370-23-011046.json","markdown":"https://secwatch.observer/filing/0001558370-23-011046.md","text":"https://secwatch.observer/filing/0001558370-23-011046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023011046/0001558370-23-011046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023011046/capr-20230612x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:49:57.044885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64bc8a5b9cb2862cc10244b69ef5a673d261d6bc","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on named executive officer compensation at the 2023-06-12 meeting.","evidence_excerpt":"FOR AGAINST ABSTAIN BROKER NON-VOTES 4,328,964 2,446,891 181,541 9,390,463","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023011046/0001558370-23-011046-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-12"}],"fact_type":"shareholder_vote"},{"claim_id":"87433560e1de5133511fefcdda46d85c49500e77","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Election of seven nominees to the Board of Directors to serve until the 2024 annual meeting at the 2023-06-12 meeting.","evidence_excerpt":"FOR WITHHELD BROKER NON-VOTES Frank Litvack, M.D. 5,848,468 1,108,927 9,390,464 Linda Marbán, Ph.D. 5,897,612 1,059,784 9,390,463 David B. Musket 4,907,731 2,049,664 9,390,464 George W. Dunbar, Jr. 5,838,850 1,118,545 9,390,464 Louis Manzo 5,887,307 1,070,088 9,390,464 Earl M. (Duke) Collier, Jr. 5,439,575 1,517,820 9,390,464 Karimah Es Sabar 5,899,808 1,057,588 9,390,463","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023011046/0001558370-23-011046-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-12"}],"fact_type":"shareholder_vote"},{"claim_id":"9d4f0df45ba9c222bffcc7dfd0b6c093bf25763e","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Approval of an amendment to the Certificate of Incorporation regarding officer exculpation at the 2023-06-12 meeting.","evidence_excerpt":"FOR AGAINST ABSTAIN BROKER NON-VOTES 5,037,656 1,816,404 103,335 9,390,464","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023011046/0001558370-23-011046-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-12"}],"fact_type":"shareholder_vote"},{"claim_id":"d2a6ef9c6194824cba785c0cdba09d7cda8f6c2f","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Rose, Snyder & Jacobs LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-12 meeting.","evidence_excerpt":"FOR AGAINST ABSTAIN BROKER NON-VOTES 14,556,113 448,170 1,343,576 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023011046/0001558370-23-011046-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-12"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}